Zoetis Inc. (NYSE:Zts) is among the the most profitable health stocks to buy. On January 15, Stifel Nicolaus analyst Jonathan Block reaffirmed a Hold rating and a $130 price target on Zoetis Inc. (NYSE:ZTS). As the lowest 1-year target price among Wall Street analysts, the company’s target translates to a potential upside of 4.91%.

Later on January 22, Piper Sandler downgraded Zoetis Inc. (NYSE:ZTS) from overweight to neutral, while cutting its price target to $135 from $190. While bullish on the company’s long-term portfolio, the company is still not comfortable with projections for the next few years until more of the company’s innovations hit the market. That said, the company “is in an innovation air pocket that could last one to two years,” according to the analyst.

Jenoche/Shutterstock.com

Morgan Stanley also cut their price target on Zoetis Inc. (NYSE:ZTS) to $160 from $175 and maintained an overweight rating on December 18. The firm believes there is an “attractive backdrop for alpha-generation opportunities” for healthcare companies in 2026. On the other hand, managed care stocks have underperformed 2025 and unprecedented politics. reimbursement and use against,” the analyst concluded.

​Zoetis Inc. (NYSE:ZTS) is a New Jersey-based provider of various healthcare products, including animal health drugs, vaccines, biodevices and genetic testing. Established in 1950, the company is dedicated to becoming the most valuable animal health company.

While we recognize the potential of ZTS as an investment, we believe certain AI stocks offer greater upside potential and less downside risk. If you’re looking for an extremely undervalued AI stock that will also benefit significantly from Trump-era tariffs and the onshoring trend, check out our free report on the best short term AI stock.

READ THE FOLLOWING: The best and worst Dow stocks for the next 12 months i 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: no.